Cosman, Felicia McMahon, Donald Dempster, David Nieves, Jeri W
Published in
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
In the absence of an intervening antiresorptive agent, cyclic administration of teriparatide does not increase bone mineral density (BMD) more than standard daily therapy. Because denosumab is a potent antiresorptive agent with a rapid off-effect, we hypothesized that it might be the optimal agent to help maximize bone gains with cyclic teriparatid...
Niimi, Rui Kono, Toshibumi Nishihara, Atsushi Hasegawa, Masahiro Kono, Toshihiko Sudo, Akihiro
Published in
JBMR plus
There is no consensus on an optimal treatment after daily teriparatide (TPTD). We performed a prospective, randomized, open-label, 12-month trial to investigate the efficacy of follow-up treatment after daily TPTD treatment for Japanese patients. Three-hundred patients were enrolled in this study. Patients received oral bisphosphonate (BP) includin...
Dempster, David W Zhou, Hua Ruff, Valerie A Melby, Thomas E Alam, Jahangir Taylor, Kathleen A
Published in
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Previously, we reported on bone histomorphometry, biochemical markers, and bone mineral density distribution after 6 and 24 months of treatment with teriparatide (TPTD) or zoledronic acid (ZOL) in the SHOTZ study. The study included a 12-month primary study period, with treatment (TPTD 20 μg/d by subcutaneous injection or ZOL 5 mg/yr by intravenous...
Nicol, Lindsey Wang, Ying Smith, Rosamund Sloan, John Nagamani, Sandesh Cs Shapiro, Jay Lee, Brendan Orwoll, Eric
Published in
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Sclerostin (SOST), a glycoprotein primarily derived from osteocytes, is an important regulator of bone remodeling. Osteogenesis imperfecta (OI) is a heritable disorder of bone characterized by low bone mass, bone fragility, recurrent fractures, and bone deformities. Altered SOST-mediated signaling may have a role in pathogenesis of type I collagen-...
Dempster, David W Zhou, Hua Recker, Robert R Brown, Jacques P Recknor, Christopher P Lewiecki, E Michael Miller, Paul D Rao, Sudhaker D Kendler, David L Lindsay, Robert
...
Published in
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
There has been renewed interest of late in the role of modeling-based formation (MBF) during osteoporosis therapy. Here we describe early effects of an established anabolic (teriparatide) versus antiresorptive (denosumab) agent on remodeling-based formation (RBF), MBF, and overflow MBF (oMBF) in human transiliac bone biopsies. Postmenopausal women ...
Lewiecki, E Michael Blicharski, Tomasz Goemaere, Stefan Lippuner, Kurt Meisner, Paul D Miller, Paul D Miyauchi, Akimitsu Maddox, Judy Chen, Li Horlait, Stephane
...
Context: Globally, one in five men aged >50 years is predicted to experience an osteoporotic fracture. Because of the treatment gap in osteoporosis and the paucity of bone-forming agents for men, new osteoporosis treatments are needed. Objective: To evaluate the safety and efficacy of romosozumab in men with osteoporosis. Design: Phase III randomiz...
Keaveny, Tony M Crittenden, Daria B Bolognese, Michael A Genant, Harry K Engelke, Klaus Oliveri, Beatriz Brown, Jacques P Langdahl, Bente L Yan, Chris Grauer, Andreas
...
Published in
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Romosozumab is a monoclonal antibody that inhibits sclerostin and has been shown to reduce the risk of fractures within 12 months. In a phase II, randomized, placebo-controlled clinical trial of treatment-naïve postmenopausal women with low bone mass, romosozumab increased bone mineral density (BMD) at the hip and spine by the dual effect of increa...
Kim, Kyoung Min Lee, Sae Young Rhee, Yumie
Published in
JBMR plus
Recombinant human parathyroid hormone (PTH) is the key anabolic agent used for preventing fracture in postmenopausal women with osteoporosis. In bone metabolism, PTH signaling is mediated through a G protein-coupled receptor that affects various post-receptor signaling pathways. Results of preclinical and clinical studies have shown that PTH improv...
Cosman, Felicia Nieves, Jeri W Dempster, David W
Published in
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
The effects of anabolic medications (teriparatide [TPTD] and parathyroid hormone [PTH]) differ in patients who have received recent treatment with potent antiresorptives. This perspective reviews studies evaluating bone density (BMD) and histomorphometric effects of treatment sequences beginning with TPTD/PTH followed by potent antiresorptives and ...
Tsai, Joy N Uihlein, Alexander V Burnett-Bowie, Sherri-Ann M Neer, Robert M Zhu, Yuli Derrico, Nicholas Lee, Hang Bouxsein, Mary L Leder, Benjamin Z
Published in
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Combined teriparatide and denosumab increases spine and hip bone mineral density more than either drug alone. The effect of this combination on skeletal microstructure and microarchitecture, however, is unknown. Because skeletal microstructure and microarchitecture are important components of skeletal integrity, we performed high-resolution periphe...
